Advanced Medicine Partners
Advanced Medicine Partners (AMP) was formed as a wholly owned subsidiary of Jaguar Gene Therapy. AMP has the leading team of CMC experts (~45) in the gene therapy space. AMP has a proven development platform and has developed a robust and reproducible AAV manufacturing process. AMP’s innovative AAV process is among the most productive in the industry and consistently generates >95% functional full capsids. This manufacturing process prioritizes patient safety by producing the purest AAV medicines possible (minimize product and process-related impurities) and drives down COGS by generating best-in-class process yields. Best-in-class analytics and characterization capabilities allow AMP to accurately quantify product dose to ensure patients get the amount of AAV product that they need. AMP’s manufacturing process has received extremely positive feedback from multiple regulatory bodies on multiple gene therapy programs.